ALZHEIMER S DISEASE
Clinical trials for ALZHEIMER S DISEASE explained in plain language.
Never miss a new study
Get alerted when new ALZHEIMER S DISEASE trials appear
Sign up with your email to follow new studies for ALZHEIMER S DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Alzheimer's drug study ends early: what we learned about AL002's safety
Disease control TerminatedThis study looked at the long-term safety of a drug called AL002 in 197 people with early Alzheimer's disease. The goal was to see how safe and tolerable the drug was over time, including checking for side effects like brain swelling or bleeding. The study was terminated early, s…
Matched conditions: ALZHEIMER S DISEASE
Phase: PHASE2 • Sponsor: Alector Inc. • Aim: Disease control
Last updated May 17, 2026 00:45 UTC
-
Alzheimer's drug TB006 safety study halted early
Disease control TerminatedThis study looked at the long-term safety of a drug called TB006 in people with Alzheimer's disease. It included people who had already taken TB006 in a previous study and new patients. The study was stopped early, and its main goal was to track side effects and how the drug move…
Matched conditions: ALZHEIMER S DISEASE
Phase: PHASE2 • Sponsor: TrueBinding, Inc. • Aim: Disease control
Last updated May 17, 2026 00:31 UTC
-
Alzheimer's drug trial cut short: SPG302 long-term study terminated
Disease control TerminatedThis study aimed to see if taking SPG302 daily for a long time is safe and helps slow Alzheimer's in people with mild-to-moderate symptoms. It included 12 adults who had already been in an earlier SPG302 study. The trial was stopped early, so results are limited.
Matched conditions: ALZHEIMER S DISEASE
Phase: PHASE2 • Sponsor: Spinogenix • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Alzheimer's drug trial halted early: no breakthrough yet
Disease control TerminatedThis study tested an experimental drug called SHR-1707 in 46 people with mild memory problems or mild Alzheimer's disease. The goal was to see if the drug could safely reduce harmful protein buildup in the brain. The trial was stopped early, so results are limited and the drug is…
Matched conditions: ALZHEIMER S DISEASE
Phase: PHASE2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC